Patent intelligence · US
US 10507225
Powder for regulating intestinal flora and protecting gastric mucosa, preparation method and use thereof
Powder for regulating intestinal flora and protecting gastric mucosa, preparation method and use thereof
Patent details — US 10507225
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 17, 2019
- Expiration
- Dec 12, 2039
- Applicant
- INFINITUS (CHINA) COMPANY LTD.
- Claims
- 1
- CPC classes
- A61K, A61K35/12, A61K36/07, A61K36/076
Quick answer
US 10507225 (Powder for regulating intestinal flora and protecting gastric mucosa, preparation method and use thereof) is held by INFINITUS (CHINA) COMPANY LTD.. Status: granted. Granted Dec 17, 2019. Expires Dec 12, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- INFINITUS (CHINA) COMPANY LTD.
- Grant date
- Expiration
- Claims
- 1
- CPC classes
- A61K, A61K35/12, A61K36/07, A61K36/076, A61K36/284, A61K36/344
More from INFINITUS (CHINA) COMPANY LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12427137
Method for reducing methane production in animal stomach
granted -
US 12421269
SGLT2/DPP4 inhibitor and application thereof
granted -
US 12403167
Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament
granted -
US 12397034
Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons
granted -
US 12389931
Oyster peptide with effect of improving sexual function and preparation method thereof
granted -
US 12383535
Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor
granted -
US 12378241
Pyridine derivative as FGFR and VEGFR dual inhibitors
granted -
US 12371434
MLL1 inhibitors and anti-cancer agents
granted
Frequently asked questions
What is US patent 10507225?
US 10507225 (Powder for regulating intestinal flora and protecting gastric mucosa, preparation method and use thereof) is held by INFINITUS (CHINA) COMPANY LTD.. Status: granted. Granted Dec 17, 2019. Expires Dec 12, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10507225?
INFINITUS (CHINA) COMPANY LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 335 pharmaceutical patents for this assignee.
When does US 10507225 expire?
Our index shows an expiration date of Dec 12, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.